“
TL;DR
This cohort study used serum metabolomics to compare 62 colorectal cancer patients and 61 healthy controls, identifying 9 metabolites that distinguish CRC and four that return to healthy levels after surgery.
Frontiers in Oncology · 7 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This cohort study used serum metabolomics to compare 62 colorectal cancer patients and 61 healthy controls, identifying 9 metabolites that distinguish CRC and four that return to healthy levels after surgery.
This study analyzed serum metabolites from 62 CRC patients (pre- and post-surgery) and 61 healthy controls using ultra-performance liquid chromatography-high resolution mass spectrometry. Statistical and pathway enrichment analyses were employed. The analysis revealed a clear distinction in metabolic profiles between CRC patients and healthy controls, with significant associations in arginine biosynthesis, pyrimidine metabolism, and pantothenate and CoA biosynthesis pathways. Four metabolites (N-Phenylacetylasparticacid, Tyrosyl-Gamma-glutamate, Tyr-Ser, and Sphingosine) showed a return to healthy levels after surgery.